NCT02022761View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

February 28, 2014

Conditions
Asthma
Interventions
DRUG

Laninamivir octanoate

40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)

Trial Locations (1)

W1G 8HU

Respiratory Clinical Trials, London

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Biota Scientific Management Pty Ltd

INDUSTRY

NCT02022761 - Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma | Biotech Hunter | Biotech Hunter